Alternating chemotherapy for first-line metastatic pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have been diagnosed with pancreatic cancer (confirmed by biopsy) that has spread to other organs.
- You have at least one tumor that can be measured on a scan (per RECIST 1.1).
- Your liver, kidney, and blood counts are within acceptable ranges (lab results from the past 14 days).
- You have not had chemotherapy for metastatic pancreatic cancer before, and you are generally able to carry out daily activities (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
This study looks at two treatment approaches for pancreatic cancer. In the first part, a new drug combo called NALIRIFOX is given as the first treatment. In the second part, researchers test whether a special antibiotic can make a common chemo work better by targeting gut bacteria.
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
This trial tests a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, as the first treatment for pancreatic cancer that has spread. The goal is to shrink tumors and improve survival.
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.